NCT02845908 is a Phase 2 clinical trial of POF in Malignant Neoplasm of Stomach Stage IV, sponsored by Fujian Cancer Hospital.

Who is sponsoring NCT02845908?

NCT02845908 is sponsored by Fujian Cancer Hospital.

What drugs are being tested in NCT02845908?

Interventions in NCT02845908: POF, FOLFOX, FOLFOX plus PAC(ip).

What condition does NCT02845908 study?

NCT02845908 studies Malignant Neoplasm of Stomach Stage IV.

Is NCT02845908 still recruiting?

NCT02845908 is currently completed. Last updated 22 April 2021.

Last reviewed 2021-04-22 · How we verify

NCT02845908

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study of POF(Paclitaxel/Oxaliplatin/5-Fluorouracil/Leucovorin) Versus FOLFOX Versus FOLFOX Plus Intraperitoneal Paclitaxel as a First-line Treatment in Advanced Gastric Cancer

Completed Phase 2 Last updated 22 April 2021

What this trial tests

Phase 2 trial testing POF in Malignant Neoplasm of Stomach Stage IV in 90 participants. Completed in 1 May 2020.

Timeline

1 November 2015

Primary endpoint
1 May 2018

1 May 2020

Quick facts

Lead sponsor	Fujian Cancer Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	1 November 2015
Primary completion	1 May 2018
Estimated completion	1 May 2020
Sites	1 location across China

Drugs / interventions tested

POF — full drug profile →
FOLFOX (folfox) — full drug profile →
FOLFOX plus PAC(ip) — full drug profile →

Conditions studied

Malignant Neoplasm of Stomach Stage IV — all drugs for Malignant Neoplasm of Stomach Stage IV →

Sponsor

Fujian Cancer Hospital

Who can join

Adults 18 to 75, any sex, with Malignant Neoplasm of Stomach Stage IV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Progression-Free Survival,PFS
Time frame: 9 month
The length of time from enrollment until the time of progression of disease (PFS, progression-free survival).

Sponsor's own description

The aim of this study was to compare the efficacy and safety of POF, FOLFOX, and FOLFOX plus paclitaxel(ip) as first-line treatment in AGC a phase II clinical trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of POF

Trials testing the same drug.

NCT04174339 — PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer · NA · unknown
NCT04155671 — POF Versus FOLFOX Plus IP Paclitaxel in AGC · Phase 2 · unknown
NCT03788226 — A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively · Phase 3 · unknown
NCT03244774 — Phase I Study of the Combination of Apatinib and POF · Phase 1 · unknown

Other Fujian Cancer Hospital trials

Trials by the same sponsor.

NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02845908 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
Last refreshed: 22 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02845908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing